Skip to main content
The power to target muscle to
stop or reverse disease progression

Scientific Publications & Presentations

May 17, 2023
The FORCE™ Platform Delivers Oligonucleotides to the Brain in a DM1 Mouse Model and in NHPs Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
April 22-27, 2023
ACHIEVE Trial, a Randomized, Placebo-Controlled, Multiple Ascending Dose Study of DYNE-101 in Individuals With Myotonic Dystrophy Type 1 (DM1)
Presented at the American Academy of Neurology (AAN) Annual Meeting Oral Presentation Poster
March 19-22, 2023
March 19-22, 2023
March 19-22, 2023
October 11–15, 2022
Building a FORCE platform-based DMD franchise for the treatment of individuals with mutations amenable to exon skipping Presented at the 27th International Hybrid Annual Congress of the World Muscle Society
May 14, 2021